Stifel Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $50

Futu NewsJan 8 20:34 · Ratings

Stifel Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $50

Futu NewsJan 8 07:31 · Ratings

FDA Issues Draft Guidance on Developing Weight Loss Drugs

Seeking AlphaJan 8 00:53

SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?

Seeking AlphaJan 6 06:32

The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination

Yahoo FinanceDec 25, 2024 03:40